《美國股市》美股再創收市新高 道指漲203點
美股上揚,三大指數皆創收市新高,因美國藥廠輝瑞(PFE.US)研究出口服新冠藥物,加上美國就業數據表現理想,。
道瓊斯工業指數升203.76點或0.56%,收報36,327.95點。
標準普爾500指數升17.47點或0.37%,報4,697.53點。
納斯達克指數升31.28點或0.2%,報15,971.59點。
輝瑞(PFE.US)口服新冠藥物能大幅降低住院及死亡風險,股價收升10.86%至48.61美元。同時消息亦刺激旅遊股上漲,標普1500航空股指數急升7%,郵輪運營商嘉年華(CCL.US)及皇家加勒比遊輪 (RCL.US)分別升8.35%及8.95%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.